title: [Evaluation of living donor liver transplantation for patients with hepatocellular carcinoma].
abstract: OBJECTIVE
  To evaluate the donor risks and potential recipient benefits of living donor liver transplantation (LDLT) for adult patients with hepatocellular carcinoma (HCC).
  
  
  METHODS
  From January 2002 to December 2006, a total of 27 LDLT for HCC patients were performed in our center, of which 25 received right lobe grafts and 2 received dual grafts. The clinical and follow-up data of these 27 recipients and 29 donors were analyzed retrospectively.
  
  
  RESULTS
  Of the 29 donors, the overall complication rate was 17.24% (5 cases). Two cases (6.90%) experienced major complications (one with intra-abdominal bleeding and one with portal vein thrombosis) and three cases (10.34%) experienced minor ones (fat necrosis and infection of the surgical skin wound in one, pleural effusion in another and transient chyle leakage in the third). All donors were fully recovered and returned to their previous work. No recipients developed small-for-size syndrome. The overall HCC patients survival rate at 1- and 3-years was 84.01% and 71.40%, respectively, similar to that of patients undergoing LDLT for various nonmalignant diseases during the same period (P > 0.05).
  
  
  CONCLUSIONS
  Although further study is needed to fully assess the risks and benefits of LDLT for the HCC patients and donors, our present results preliminarily suggest that LDLT offers an acceptable chance and duration of survival in patients with HCC, and it is a relatively safe procedure.
authors.affiliation: Center of Liver Transplantation, West China Hospital, Sichuan University, Chengdu 610041, China.
authors.forename: Xiao-zhong
authors.initials: XZ
authors.lastname: Jiang
authors.forename: Lv-nan
authors.initials: LN
authors.lastname: Yan
authors.forename: Bo
authors.initials: B
authors.lastname: Li
authors.forename: Tian-fu
authors.initials: TF
authors.lastname: Wen
authors.forename: Yong
authors.initials: Y
authors.lastname: Zeng
authors.forename: Ji-chun
authors.initials: JC
authors.lastname: Zhao
authors.forename: Wen-tao
authors.initials: WT
authors.lastname: Wang
authors.forename: Jia-yin
authors.initials: JY
authors.lastname: Yang
authors.forename: Ming-qing
authors.initials: MQ
authors.lastname: Xu
authors.forename: Zhe-yu
authors.initials: ZY
authors.lastname: Chen
authors.forename: Yu-kui
authors.initials: YK
authors.lastname: Ma
authors.forename: Fu-gui
authors.initials: FG
authors.lastname: Li
authors.forename: Guang
authors.initials: G
authors.lastname: Gong
mesh_terms: D000328:Adult; D006528:Carcinoma, Hepatocellular / Q000401:mortality / Q000601:surgery*; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000401:mortality / Q000601:surgery*; D016031:Liver Transplantation / Q000009:adverse effects / Q000379:methods / Q000401:mortality; D019520:Living Donors; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D018570:Risk Assessment; D013534:Survival; D055815:Young Adult